^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Cholangiocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    ESMO 2020
    Title:

    133P - HER2 transcription status of diverse solid tumours with clinical implications

    Published date:
    09/14/2020
    Excerpt:
    We identified 7 pts that were given Anti-HER2 therapy (Tx). One pt with metastatic cholangiocarcinoma mRNA+ (CNV and IHC unable to perform) achieved durable partial response with dual-anti-Her2 Tx (trastuzumab and lapatinib) (PFS: 24+ months).
    Secondary therapy:
    Chemotherapy